Trend of salvage treatment in diffuse large B cell lymphoma 
in the outpatient chemotherapy era

Nakaya,Aya; Fujita,Shinya; Satake,Atsushi; Nakanishi,Takahisa; Azuma,Yoshiko; Tsubokura,Yukie; Saito,Ryo; Konishi,Akiko; Hotta,Masaaki; Yoshimura,Hideaki; Ishii,Kazuyoshi; Ito,Tomoki; Nomura,Shosaku

doi:10.3892/mco.2019.1930

December-2019 Volume 11 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December-2019 Volume 11 Issue 6

Full Size Image

Article Open Access

Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era

Authors:
- Aya Nakaya
- Shinya Fujita
- Atsushi Satake
- Takahisa Nakanishi
- Yoshiko Azuma
- Yukie Tsubokura
- Ryo Saito
- Akiko Konishi
- Masaaki Hotta
- Hideaki Yoshimura
- Kazuyoshi Ishii
- Tomoki Ito
- Shosaku Nomura
View Affiliations / Copyright

Affiliations: First Department of Internal Medicine, Kansai Medical University, Hirakata, Osaka 573‑1010, Japan

Copyright: © Nakaya et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 557-562
|
Published online on: October 3, 2019

https://doi.org/10.3892/mco.2019.1930
Expand metrics +

Abstract

Patients with diffuse large B cell lymphoma (DLBCL) who have failed to achieve complete remission with first‑line therapy can subsequently receive salvage therapy. However, there is no definite consensus on the use of salvage therapy, and little information on the optimal treatment regimen. The present study retrospectively analyzed data from 131 patients diagnosed with DLBCL between April 2002 and November 2017 who relapsed and received salvage therapy. Primary treatment included R‑CHOP or R‑CHOP‑like regimens. The most common salvage regimen was R‑DeVIC (42%), followed by R‑ESHAP (23%), other aggressive regimens (12%) and palliative therapy (23%). The median overall survival (OS) was 45.7 months for R‑DeVIC, 41.8 months for palliative therapy, 29.4 months for R‑ESHAP, and 28.5 months for aggressive regimens (P=0.937). A total of 25 patients underwent autologous stem cell transplantation (ASCT), and the OS was 75.6 months for these patients compared with 33.5 months (range, 25.6‑45.6 months) for patients who did not undergo ASCT (P=0.033). Following the establishment of an outpatient chemotherapy unit in 2014, R‑DeVIC use became more common, increasing from 37% prior to 2014 to 46% after 2014, whereas R‑ESHAP use decreased (31 to 17%). The present study did not identify the optimal salvage regimen for patients with DLBCL. However, salvage ASCT improved the outcome, and regimens administered via peripheral veins were demonstrated to be more common in outpatient chemotherapy settings.

View Figures

View References

1	Friedberg JW: Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011:498–505. 2011. View Article : Google Scholar : PubMed/NCBI
2	Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den, Salles G, Gaulard P, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 346:235–242. 2002. View Article : Google Scholar : PubMed/NCBI
3	Feugier P, Van Hoof, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 23:4117–4126. 2005. View Article : Google Scholar : PubMed/NCBI
4	Gisselbrecht C, Glass B, Mounier N, Singh Gill, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 28:4184–4190. 2010. View Article : Google Scholar : PubMed/NCBI
5	Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, Rubinger M, Buckstein R, Imrie KR, Federico M, et al: Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 32:3490–3496. 2014. View Article : Google Scholar : PubMed/NCBI
6	Crump M, Neelapu SS, Farooq U, Van Den, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al: Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study. Blood. 130:1800–1808. 2017. View Article : Google Scholar : PubMed/NCBI
7	Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M and Loeffler M: Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+B-cell lymphoma in the rituximab era. J Clin Oncol. 28:2373–2380. 2010. View Article : Google Scholar : PubMed/NCBI
8	Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, et al: An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 123:837–842. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles